Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 7, 2025
Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date
Read more at globenewswire.com
